Valganciclovir + CMV hyperimmune globulin + Valganciclovir
ApprovedCompleted 1 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Cytomegalovirus Disease
Conditions
Cytomegalovirus Disease
Trial Timeline
Nov 1, 2011 → Dec 1, 2015
NCT ID
NCT01509404About Valganciclovir + CMV hyperimmune globulin + Valganciclovir
Valganciclovir + CMV hyperimmune globulin + Valganciclovir is a approved stage product being developed by CSL for Cytomegalovirus Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01509404. Target conditions include Cytomegalovirus Disease.
What happened to similar drugs?
6 of 20 similar drugs in Cytomegalovirus Disease were approved
Approved (6) Terminated (3) Active (11)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01509404 | Approved | Completed |
Competing Products
20 competing products in Cytomegalovirus Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| mRNA-1273 | Moderna | Phase 1 | 0 |
| mRNA-1647 | Moderna | Phase 2 | 0 |
| mRNA-1647 | Moderna | Phase 2 | 0 |
| mRNA-1647 | Moderna | Phase 2 | 0 |
| mRNA-1647 | Moderna | Phase 2 | 0 |
| mRNA-1647 | Moderna | Phase 1 | 0 |
| mRNA-1647 | Moderna | Phase 2 | 0 |
| mRNA-1647 | Moderna | Phase 1 | 0 |
| mRNA-1647 | Moderna | Phase 3 | 0 |
| ASP0113 + Placebo | Astellas Pharma | Phase 2 | 35 |
| ASP0113 + Placebo | Astellas Pharma | Phase 3 | 40 |
| Letermovir oral granules + Letermovir tablet + Letermovir intravenous | Merck | Phase 2 | 35 |
| Letermovir 240 mg Oral Tablet | Merck | Phase 2 | 42 |
| Letermovir tablet + Letermovir IV | Merck | Phase 3 | 40 |
| Letermovir | Merck | Phase 1 | 36 |
| Letermovir | Merck | Approved | 43 |
| Letermovir 480 MG [Prevymis] | Merck | Phase 2 | 42 |
| V160 Low Dose IM + V160 Medium Dose IM + V160 High Dose IM + V160 Medium Dose plus Merck Aluminum Phosphate Adjuvant (MAPA) 225 µg /dose IM + V160 High Dose plus MAPA 225 µg /dose IM + V160 Maximum Dose IM + V160 Medium Dose ID | Merck | Phase 1 | 29 |
| Ganciclovir | Merck | Pre-clinical | 26 |
| Letermovir + Placebo | Merck | Phase 3 | 40 |